

FIRST LIGHT

11 February 2026

RESEARCH

JUBILANT FOODWORKS | TARGET: Rs 676 | +22% | BUY

Robust Performance

AMBER ENTERPRISES | TARGET: Rs 8,700 | +16% | BUY

Q3 rebound; all-round performance with Electronics gearing up

EICHER MOTORS | TARGET: Rs 6,931 | -5% | HOLD

On the right track; valuations factored fully

AUROBINDO PHARMA | TARGET: Rs 1,294 | +15% | BUY

In-line result; Europe to be the key growth driver

ESCORTS KUBOTA | TARGET: Rs 2,828 | -26% | SELL

Healthy Q3 show; medium-term woes continue; retain SELL

THE RAMCO CEMENTS | TARGET: Rs 830 | -31% | SELL

Performance shortfall continues; no respite in medium term

P N GADGIL JEWELLERS | TARGET: Rs 734 | +23% | BUY

Execution holds; growth outlook moderated

SUMMARY

JUBILANT FOODWORKS

- Domino's India maintains a steady momentum with consistent growth and a dominant share in the Delivery channel
- Management guided for 5–7% LFL growth stated that company does not see any near-term demand headwinds
- International operations remain stable, contributing positively to consolidated performance. BUY rating with TP of 676, based on SOTP

[Click here](#) for the full report.

BOBCAPS Research
research@bobcaps.in



AMBER ENTERPRISES

- Q3 Revenue/ EBITDA were 22%/ 42% ahead of estimates, driven by strong growth in Electronics (+79% YoY) and CD (+30% YoY)
- EBITDA margin expanded ~80bps YoY/280 bps QoQ, led by Electronics margin inflection
- Revise estimates, roll forward to Dec'27 EPS; TP at Rs 8,700 (unchanged 42x multiple). Upgrade to BUY

[Click here](#) for the full report.

EICHER MOTORS

- RE volumes drive topline Q3FY26; SA revenue grew by 22% on robust domestic growth of 24% YoY. Mid-size share at ~89%
- VECV paces strongly with volumes up 24%; Parts business revenue up by 14% YoY, driven by higher utilisation
- Revise FY27/FY28 EBITDA estimates by 2% each. We assign 30x P/E and roll forward to arrive at SOTP-based TP of Rs 6,931. Maintain HOLD

[Click here](#) for the full report.

AUROBINDO PHARMA

- Sales/EBITDA/PAT were 1%/-0.4%/4% below our estimates. Adjusting for a one-time expense of Rs 653 mn, APAT was 2.5% above estimates
- Pen-G manufacturing capacity to likely increase to 10k tons p.a., in FY27E, which would trigger Rs ~2.4bn PLI income in FY27E
- Increased ascribe PE to 16x(earlier 15x) as ARBP shifting towards Biopharma to arrive at PT of Rs 1294 (earlier PT Rs 1,316) Maintain BUY

[Click here](#) for the full report.

ESCORTS KUBOTA

- Strong tractor momentum continued with volumes up ~14% YoY, driving Agri Machinery EBIT margin higher to 13.5% (+310 bps YoY)
- Operating leverage and cost control drive gross margin expansion of 200bps YoY to 29%. Cost inflation expected to impact Q4FY26
- Revise up FY26E/FY27E/FY28E EBITDA/EPS to factor 9MFY26 show. Retain 20x P/E multiple, revise TP down to Rs 2,828 (Rs 2,731). SELL

[Click here](#) for the full report.

THE RAMCO CEMENTS

- Overall volumes grew 5% YoY. Subdued realisations (+1% YoY) on weak East pricing, kept revenue growth modest at 6% YoY
- TN mineral tax and higher fuel costs led to EBITDA margin contraction (~80bps YoY), despite higher green power and lower logistics costs
- Retain FY27E/FY28E EBITDA, will diligently watch cement prices; assign 10x multiple and revise TP to Rs830 (vs Rs790). Maintain SELL

[Click here](#) for the full report.

P N GADGIL JEWELLERS

- Festive-led demand, led by SSSG (33%), drives 35.6% YoY revenue growth; retail/e-com up 46.3%/140%
- ~450bps gross margin expansion and operating leverage lift EBITDA ~99% YoY
- Growth momentum to continue on strong store additions and jewellery demand; maintain BUY; TP of Rs 734 per share

[Click here](#) for the full report.

BUY**TP: Rs 676 | ▲ 22%****JUBILANT FOODWORKS**

Consumer Discretionary

11 February 2026

Robust Performance

- Domino's India maintains a steady momentum with consistent growth and a dominant share in the Delivery channel
- Management guided for 5–7% LFL growth stated that company does not see any near-term demand headwinds
- International operations remain stable, contributing positively to consolidated performance. BUY rating with TP of 676, based on SOTP

Lavita Lasrado

Research Analyst

research@bobcaps.in

Result Highlights: JFL standalone revenue came at Rs18 bn; up 11.8% YoY led by 5% growth in LFL. Gross margin stood at 71.6%, down 42bps YoY. EBITDA grew 20% to Rs 4.8bn while EBITDA margin came in flat at 19.8%. The company added 114 new stores during the quarter (Dominos 93) with total store network across all brands and countries now being 3,594 stores. Delivery channel mix for Domino's India stood at 74.9%. Domino's app MAU came in at 17 mn; up 28%. Domino's India continued to lead growth with 5% LFL, aided by the traction in delivery and steady new store additions (93 stores in Q3, now 511 cities).

Healthy Q3 performance with broad-based growth JFL reported a healthy Q3 driven by recovery in Domino's India and continued improvement in international operations. Product innovation remains a key growth lever with launches like "Cheese lava pull apart" gaining traction. Popeyes recorded high double-digit SSSG, a strong traction in the roll-out of "Flavour burst burgers", and improving profitability. In Turkey, Domino's reported 6.3% LFL growth (adjusted for inflation), underscoring the segment's continued profitability and stability post-acquisition. Overall, JFL demonstrated balanced growth across geographies and brands, rising profitability, and visible traction from digital, product, and delivery-led innovations, setting up well for sustained earnings momentum in 9MFY26.

Our View: We believe margin recovery is underway, supported by premiumisation, cost efficiencies, and disciplined expansion. The consistent double-digit growth in Domino's India, improving traction in Popeyes, and steady profitability in Turkey highlight the strength of its diversified QSR portfolio. We model revenue/EBITDA CAGRs of 7.9%/8.3% over FY26–28E. Basis this, we maintain BUY, valuing Jubilant using SOTP valuation methodology comprising: 1) India business at 35x EV/EBITDA (pre-IND-AS) 2) DP Eurasia on 35x PE ratio, with a revised price of Rs 676.

Ticker/Price	JUBI IN/Rs 554
Market cap	US\$ 4.0bn
Free float	60%
3M ADV	US\$ 13.2mn
52wk high/low	Rs 728/Rs 481
Promoter/FPI/DII	40%/19%/35%


Source: NSE | Price as of 10 Feb 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	81,417	92,732	106,498
EBITDA (Rs mn)	15,722	17,565	20,932
Adj. net profit (Rs mn)	2,171	3,348	4,676
Adj. EPS (Rs)	3.3	5.1	7.1
Consensus EPS (Rs)	3.3	5.7	7.9
Adj. ROAE (%)	10.3	14.1	17.0
Adj. P/E (x)	168.5	109.3	78.2
EV/EBITDA (x)	23.3	20.8	17.5
Adj. EPS growth (%)	(45.9)	54.2	39.7

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



BUY

TP: Rs 8,700 | ▲ 16%

AMBER ENTERPRISES

Consumer Durables

10 February 2026

Q3 rebound; all-round performance with Electronics gearing up

- Q3 Revenue/ EBITDA were 22%/ 42% ahead of estimates, driven by strong growth in Electronics (+79% YoY) and CD (+30% YoY)
- EBITDA margin expanded ~80bps YoY/280 bps QoQ, led by Electronics margin inflection
- Revise estimates, roll forward to Dec'27 EPS; TP at Rs 8,700 (unchanged 42x multiple). Upgrade to BUY

Vineet Shanker
Research Analyst
Amey Tupe
Research Associate
research@bobcaps.in

Strong Q3 recovery; Electronics drives consolidated margin improvement:

Amber delivered a strong Q3FY26 performance, with consolidated revenue rising 38% YoY to Rs 29.4bn, driven by robust growth in Consumer Durables & Electronics. Operating EBITDA grew 55% YoY to Rs 2.47bn, with margin expanding 90bps YoY to 8.4%, supported by a favourable mix, operating leverage and sharp improvement in the profitability of Electronics. Adjusted PAT (pre-exceptional) rose 111% YoY to Rs 0.76bn, aided by higher operating profitability.

Consumer Durables revenue growth rebounds; diversification strategy

supports growth: Segment revenue grew 30% YoY to Rs 20.1bn, supported by (a) diversified product portfolio (RAC, Commercial AC), (b) improving wallet share with existing customers (c) increasing traction in non-AC components and commercial AC products. Segment EBITDA grew 24% YoY to Rs 1.4bn, with margin at 7.1% (down 33bps YoY), reflecting continued input cost pressures and seasonality. Management reiterated confidence in outperforming the industry and maintained FY26 growth guidance of 13-15% for the division.

Electronics delivers a breakout quarter; EBITDA margin hits double digits:

Electronics revenue grew 79% YoY to Rs 8.5bn, on the back of strong traction in PCBA, scaling up of bare PCB and contribution from newer verticals (power electronics/industrial automation). EBITDA surged 153% YoY to Rs 0.86bn, with margins expanding to 10.2% (vs 7.2% in Q3FY25); marking the first double-digit quarter. Management reiterated confidence in sustaining double-digit EBITDA margins by FY27.

Railways steady; capex cycle and Defence opportunity to drive scale-up: The division reported 20% YoY revenue growth to Rs 1.3bn, led by execution across Railways, Metro projects and Defence applications. EBITDA increased to Rs 0.18bn, though margins remain modest, given the project execution mix. Management highlighted strong opportunity tailwinds, driven by railway capex allocation and the announcement of seven high-speed rail corridors, while reiterating confidence of scaling the business meaningfully over the next two years.

Key changes

Target	Rating
▲	▲

Ticker/Price	AMBER IN/Rs 7,511
Market cap	US\$ 2.8bn
Free float	60%
3M ADV	US\$ 21.8mn
52wk high/low	Rs 8,626/Rs 5,235
Promoter/FPI/DII	40%/24%/14%


Source: NSE | Price as of 10 Feb 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	99,730	1,24,936	1,59,610
EBITDA (Rs mn)	7,634	9,318	13,142
Adj. net profit (Rs mn)	2,436	3,085	5,464
Adj. EPS (Rs)	72.3	87.8	155.4
Adj. ROAE (%)	11.2	10.5	14.1
Adj. P/E (x)	103.9	85.6	48.3
EV/EBITDA (x)	33.1	27.2	19.3
Adj. EPS growth (%)	83.3	21.4	77.1

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



HOLD

TP: Rs 6,931 | ▼ 5%

EICHER MOTORS

| Automobiles

| 11 February 2026

On the right track; valuations factored fully

- RE volumes drive topline Q3FY26; SA revenue grew by 22% on robust domestic growth of 24% YoY. Mid-size share at ~89%
- VECV paces strongly with volumes up 24%; Parts business revenue up by 14% YoY, driven by higher utilisation
- Revise FY27/FY28 EBITDA estimates by 2% each. We assign 30x P/E and roll forward to arrive at SOTP-based TP of Rs 6,931. Maintain HOLD

Milind Raginwar
Research Analyst
research@bobcaps.in

Steady volume momentum sustains revenue growth: EIM's SA revenue grew 22% YoY to ~Rs59.9bn, driven by a strong traction in refreshed models. Domestic 2W sales rose to ~300k units (+24% YoY), while exports came at ~25k units (down YoY). ASP per vehicle fell at ~Rs161k (-11% YoY) amid the continued discounting push. Domestic market remains a stronghold with mid-size segment share improving to ~89%. Consolidated revenue (including VECV) rose ~23% YoY to Rs61.1bn.

Pricing and operating leverage aid margin amid commodity inflation: RM cost rose ~22% YoY (flat QoQ) due to commodity inflation ~70 bps net impact. Gross margins added ~94bps (-12bps YoY), aided by operating leverage, better model and geography mix, value engineering (~20 bps benefit) and price hikes (~140 bps YTD impact). Other expenses came at 5% QoQ, due to lower marketing expenses.

Product refreshes/launches sustain leadership: Refreshes and launches (Hunter 350 & Scram 440 in Nepal, Bear 650 in Argentina, Guerrilla 450 in Brazil) kept the momentum alive. <350cc segment continues to anchor volume, while 650cc segment witnessing demand revival post GST rationalisation. Management highlighted a favourable demographic shift post-GST, with ~40% of Hunter buyers aged 23–24 years, indicating increasing penetration among the younger customers.

VECV volumes improve; early signs of recovery visible: VECV delivered strong Q3FY26 with ~26k units (+24% YoY), taking YTD to ~70k units (+13% YoY). Parts business maintained double-digit growth of 14%, driven by higher utilisation.

Revise estimates and maintain HOLD: We revise our FY27/FY28 EBITDA estimates by 2% each due to better product portfolio, focus on mid-segment category, rate cut demand boost to 2Ws and improving exports. The revised EBITDA/PAT CAGR is at 14%/14% over FY25-FY28E. We value EIM at 30x P/E to factor in healthier prospects in the RE segment, regained dominating market share, strong exports aided by CKD, boost to the VECV segment all aiding margins. We arrive at a higher SOTP-based TP of Rs 6,931 (vs Rs 6,436) on rollover that includes Rs 180/sh for VECV (earlier Rs150) on better prospects. Maintain HOLD.

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	EIM IN/Rs 7,296
Market cap	US\$ 22.0bn
Free float	51%
3M ADV	US\$ 37.2mn
52wk high/low	Rs 7,614/Rs 4,646
Promoter/FPI/DII	49%/30%/9%


Source: NSE | Price as of 10 Feb 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	1,84,515	2,17,962	2,47,211
EBITDA (Rs mn)	47,680	56,390	65,404
Adj. net profit (Rs mn)	42,329	45,971	55,947
Adj. EPS (Rs)	154.4	167.7	204.0
Consensus EPS (Rs)	154.4	175.0	199.0
Adj. ROAE (%)	22.9	22.4	23.4
Adj. P/E (x)	47.3	43.5	35.8
EV/EBITDA (x)	41.8	35.4	30.8
Adj. EPS growth (%)	12.3	8.6	21.7

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



BUY

TP: Rs 1,294 | ▲ 15%

AUROBINDO PHARMA

| Pharmaceuticals

| 10 February 2026

In-line result; Europe to be the key growth driver

- Sales/EBITDA/PAT were 1%/-0.4%/4% below our estimates. Adjusting for a one-time expense of Rs 653 mn, APAT was 2.5% above estimates
- Pen-G manufacturing capacity to likely increase to 10k tons p.a., in FY27E, which would trigger Rs ~2.4bn PLI income in FY27E
- Increased ascribe PE to 16x(earlier 15x) as ARBP shifting towards Biopharma to arrive at PT of Rs 1294 (earlier PT Rs 1,316) Maintain BUY

Foram Parekh
Research Analyst
research@bobcaps.in

In-line earnings – Sales grew by 8.4% YoY and 4.3% QoQ to Rs 86.4 bn, driven by 27% YoY growth in Europe to Rs 27bn, 2% YoY growth in the US to Rs 37.4bn and 22.5% YoY growth in the ARV segment to Rs 3.7bn; offset by 4% YoY decline in the API segment and flattish sales in the Growth Markets. Healthy product mix and better yield from the Pen-G plant resulted in a 128 bps YoY increase in the gross margin to 59.7%. However, 16% YoY rise in employee cost and 15% YoY rise in Other expenses ex.-of R&D, led to a flattish EBITDA margin YoY at 20.5%. During the quarter, there was an exceptional cost of Rs 653 mn attributed towards new labour code leading to 8% YoY growth in PAT to Rs 9.1 bn. Adjusting against this one time cost, PAT grew by 9% YoY to Rs 9.7bn. Excluding gRevlimid, sales/gross profit and EBITDA rose 9%,13%/15% respectively on YoY basis.

Europe growth on uptick in key regions – Europe sales reported 8% above our estimates, growing 27% in INR terms and 11% in CC terms. The growth was driven by new launches and healthy execution in key regions like France, Portugal, Germany and Netherlands, where each of the market has reported double-digit growth. Going forward, the company expects to maintain double-digit growth rate in cc terms, driven by new launches that include some Loss of Exclusivity products and better supplies from the China unit. Hence, we expect Europe region to grow at a CAGR of 17% from FY26 – FY28E to Rs 138bn in FY28E.

US sales driven by double-digit growth rate in injectable sales – US sales were 2% below our estimates. While in CC terms, US region reported a 4% decline, the segment reported 2% YoY growth in INR terms. The growth was supported by 17% YoY rise in injectables and 9 new launches. Going forward, the company expects sustaining double-digit growth rate in injectables, as the Vizag plant would finish installation of 8 lines by CY26 and aims to file 10 products (3 filed); leading to new launches from FY28E. The company is also hopeful of lifting the Warning letter from Eugia Unit III as 11 observations are procedural in nature. The OTC segment has also picked up well since the last three quarters and the Oral solid segment is expected to grow steadily on USD1bn base. Thus, we expect the US sales to grow at a CAGR of 5% from FY26-28E to Rs 161.6bn in FY28E

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	ARBP IN/Rs 1,124
Market cap	US\$ 7.3bn
Free float	48%
3M ADV	US\$ 15.3mn
52wk high/low	Rs 1,279/Rs 1,010
Promoter/FPI/DII	52%/18%/23%


Source: NSE | Price as of 10 Feb 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	317,250	333,525	366,797
EBITDA (Rs mn)	66,067	68,587	78,211
Adj. net profit (Rs mn)	34,825	36,195	43,601
Adj. EPS (Rs)	59.4	61.8	74.4
Consensus EPS (Rs)	59.4	61.6	75.4
Adj. ROAE (%)	11.5	10.9	11.8
Adj. P/E (x)	18.9	18.2	15.1
EV/EBITDA (x)	9.9	9.7	8.7
Adj. EPS growth (%)	3.6	3.9	20.5

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



SELL**TP: Rs 2,828 | ▼ 26%****ESCORTS KUBOTA**

Automobiles

11 February 2026

Healthy Q3 show; medium-term woes continue; retain SELL

- Strong tractor momentum continued with volumes up ~14% YoY, driving Agri Machinery EBIT margin higher to 13.5% (+310 bps YoY)
- Operating leverage and cost control drive gross margin expansion of 200bps YoY to 29%. Cost inflation expected to impact Q4FY26
- Revise up FY26E/FY27E/FY28E EBITDA/EPS to factor 9MFY26 show. Retain 20x P/E multiple, revise TP down to Rs 2,828 (Rs 2,731). SELL

Milind Raginwar
Research Analyst
 research@bobcaps.in

Volume growth drives revenue; regional disparity continues to pressure:

ESCORTS reported healthy revenue growth of ~11%/18% YoY/QoQ to Rs32.8bn, driven primarily by tractor volumes growth of ~14% YoY, supported by strong rabi demand, healthy reservoir levels and higher MSPs. However, realisation remained subdued, with NRPV down ~2% YoY due to competitive intensity; though improving ~8% QoQ on a better mix. Management highlighted that growth continues to be skewed towards South/East markets, where ESC has a relatively lower penetration.

Agri machinery drives margin expansion, CE stabilises QoQ: Agri Machinery (AM) segment stayed the key growth driver, revenue grew ~15% with EBIT margin expanding sharply to 13.5% (+310bps/72bps YoY/QoQ), aided by cost control and material cost softening. Construction Equipment (CE) segment lagged, with volumes declining ~14% YoY; though improving sharply QoQ. Segment revenue slowed ~5% YoY, with EBIT margin falling to 6.6% (-440bps YoY), albeit recovering QoQ.

Softening cost and scale drive margin: Raw material costs rose ~8% YoY to Rs20.4bn but fell to ~71% of sales (vs 73% YoY), benefiting from the scale and cost control. Gross margin added ~200bps YoY (-170bps QoQ) to ~29%. EBITDA rose ~31%/21% YoY/QoQ to Rs4.3bn, with operating margin improving to 13.3% (+196bps YoY). Management cautioned that commodity inflation (steel, copper, aluminium) is expected in Q4FY26, though no price hike has been taken yet.

Earnings aided by operating leverage: Reported PAT grew ~12%/13% YoY/QoQ to Rs3.6bn, impacted by a one-off labour code charge of Rs525mn. However, adjusted PAT, rose a strong ~42%/29% YoY/QoQ.

Maintain SELL: Intense competition, unfavourable regional mix, GST rate cuts keep tractor realisation under pressure YoY. ESCORTS has also faced challenges selling Kubota tractors given the engine manufacturing woes. We, revise our EBITDA/EPS for FY26E/FY27E/FY28E upwards. The new capacity benefits will flow from FY28 and beyond that will aid export visibility. We revise our TP to Rs 2,828 (Rs 2,731). Our target P/E stays at 20x – a small premium to the stock's LT mean. Retain SELL.

Key changes

Target	Rating
▲	◀ ▶


Ticker/Price	ESCORTS IN/Rs 3,824
Market cap	US\$ 5.6bn
Free float	63%
3M ADV	US\$ 4.2mn
52wk high/low	Rs 4,180/Rs 2,776
Promoter/FPI/DII	37%/22%/8%

Source: NSE | Price as of 10 Feb 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	1,02,439	1,18,797	1,33,727
EBITDA (Rs mn)	11,653	14,370	16,583
Adj. net profit (Rs mn)	11,268	12,826	14,569
Adj. EPS (Rs)	100.7	114.6	130.2
Consensus EPS (Rs)	100.7	126.0	133.0
Adj. ROAE (%)	10.9	11.0	11.1
Adj. P/E (x)	38.0	33.4	29.4
EV/EBITDA (x)	44.5	36.2	31.7
Adj. EPS growth (%)	6.1	13.8	13.6

Source: Company, Bloomberg, BOBCAPS Research

Stock performance

Source: NSE



SELL

TP: Rs 830 | ▼ 31%

THE RAMCO CEMENTS

Cement

10 February 2026

Performance shortfall continues; no respite in medium term

- Overall volumes grew 5% YoY. Subdued realisations (+1% YoY) on weak East pricing, kept revenue growth modest at 6% YoY
- TN mineral tax and higher fuel costs led to EBITDA margin contraction (~80bps YoY), despite higher green power and lower logistics costs
- Retain FY27E/FY28E EBITDA, will diligently watch cement prices; assign 10x multiple and revise TP to Rs830 (vs Rs790). Maintain SELL

Milind Raginwar
Research Analyst
Ayush Dugar
Research Associate
research@bobcaps.in

Modest volume growth helps revenue gains as realisations stay muted:

Cement volumes rose ~4% YoY to 4.43mt in Q3FY26, (construction chemicals volumes jumped 79% YoY to 0.15mt), lifting the overall sales volume by ~5% YoY. Revenue grew ~6% YoY (-6% QoQ) to Rs 21bn, driven by volume gains, given that realisations (average) remained subdued; up by ~1% YoY (-10% QoQ) to Rs 4,584/t. Cement capacity utilisation hovered at 73% (vs 75% YoY).

Cost inflation persists; TN mineral tax remains an overhang: Operating cost/t increased modestly by ~2% YoY (-5% QoQ) to Rs 3,972. Raw material cost/ rose ~5% YoY to Rs 979, impacted by Tamil Nadu (TN) MBIT levy (~Rs90-110/t), translating into a Rs 470mn cost impact in Q3FY26. Power & fuel costs/t jumped ~3% YoY to Rs 1,089, driven by higher fuel price at Rs1.57/kcal vs Rs1.49/kcal and adverse currency. This was partially offset by the increased green power usage (47% vs 39% YoY). Logistics declined by ~1%/3% YoY/QoQ, providing limited relief.

EBITDA compresses sharply: EBITDA was largely flat YoY at Rs 2.8bn (-27% QoQ) with EBITDA margin contracting by 77bps YoY to 13.4%. Further, EBITDA per tonne was down 1% YoY to Rs 611/t. Exceptional items stood at Rs 4.9bn, driven by land sale but offset by new labour code provisions.

Expansion plans: Capex spend was Rs 2.2bn in Q3FY26/9MFY26: Rs 8.2bn), with FY26 capex guidance trimmed to ~Rs 11bn. TRCL stays on track to reach 31mtpa cement capacity by Mar'27. The company added 2mtpa capacity at Ariyalur Plant (capex) and the brownfield expansion at Kolimigundla will add 3mtpa (vs 1.5mtpa).

Earnings maintained; retain SELL: We maintain our FY26/FY27/FY28 EBITDA/EPS estimates, penning (EPS estimates of Rs 14.0/Rs24.8/Rs34.3) Revenue/EBITDA/PAT CAGR of 15%/23%/22% over FY25-28E. In FY25/FY26 net debt to EBITDA is elevated at 3x, owing to aggressive capex, but may soften in the near term. Cost inflation is clearly a concern to EBITDA margins. We feel the current valuation of 14.0x 1YF EV/EBITDA is at a premium. We assign a 10x target multiple and revise our TP to Rs 829 (vs Rs 790) implying a replacement cost of Rs 8.1bn/mnt – a 10% premium. Maintain SELL.

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	TRCL IN/Rs 1,205
Market cap	US\$ 3.1bn
Free float	58%
3M ADV	US\$ 3.4mn
52wk high/low	Rs 1,215/Rs 788
Promoter/FPI/DII	42%/7%/32%


Source: NSE | Price as of 9 Feb 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	84,951	99,865	1,17,758
EBITDA (Rs mn)	12,318	16,329	20,664
Adj. net profit (Rs mn)	775	3,304	5,850
Adj. EPS (Rs)	3.3	14.0	24.8
Consensus EPS (Rs)	3.3	17.9	28.7
Adj. ROAE (%)	1.5	4.3	7.3
Adj. P/E (x)	367.1	86.2	48.7
EV/EBITDA (x)	19.4	14.5	11.4
Adj. EPS growth (%)	(80.4)	326.0	77.1

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



BUY**TP: Rs 734 | ▲ 23%****P N GADGIL JEWELLERS** | Retail

| 10 February 2026

Execution holds; growth outlook moderated

- Festive-led demand, led by SSSG (33%), drives 35.6% YoY revenue growth; retail/e-com up 46.3%/140%
- ~450bps gross margin expansion and operating leverage lift EBITDA ~99% YoY
- Growth momentum to continue on strong store additions and jewellery demand; maintain BUY; TP of Rs 734 per share

Lavita Lasrado
 Research Analyst
 research@bobcaps.in

Overall beat in Q3: PNGJL reported overall earnings beat in Q3FY26, with revenue growing 35.6% YoY (vs 11.3% estimated). EBITDA increased 99.0% YoY, beating our estimate by 44.9%, with EBITDA margin expanding 236bps YoY to 7.4% aided by strong gross margin expansion (+453bps YoY to 14.4%). Consequently, adjusted PAT more than doubled to Rs 1.7bn (+101.6% YoY), 61.5% ahead of estimates; reflecting strong operating leverage.

Highlights: The earnings beat was driven by a sharp acceleration in same-store performance and operating leverage. SSSG stood at 33%, supported by higher footfalls (+33%) and strong conversion (94%), translating into robust retail growth (+46.3% YoY) and strong e-commerce traction (+140% YoY). Operating leverage enabled EBITDA to grow materially ahead of revenue. The network expanded to 66 stores in Q3FY26 (61 PNG; 5 lifestyle); though the profitability outperformance was largely driven by existing-store productivity vs store additions.

Concall KTAs: Management guided for FY26 revenues to exceed the earlier guidance of Rs 95bn, potentially approaching ~Rs 100bn, supported by continued wedding demand and planned store additions. For FY27, the company targets ~20–25% revenue growth to Rs 115–120bn, on the expansion to ~105 stores (from 66 currently), including ~25 store additions with a balanced mix of PNG and Lifestyle formats. Margins are expected to normalise from Q3's seasonal peak, but remain structurally higher with sustainable annualised margins guided at ~13-14% gross, 7-7.25% EBITDA, and ~3.75–4.0% PAT.

Maintain BUY; TP cut by 5% to Rs 734: We have marginally revised our revenue and EBITDA estimates for FY27E/28E by -1.6/-4.3 and -1.3/-7.0. We estimate Revenue/EBITDA CAGR to be 22.3%/17.4% over FY26-28E, driven by strong store additions and strong jewellery demand. Our numbers build in 11.2% EPS CAGR over FY26-27E. We maintain BUY rating with TP of Rs 734 per share. Our target P/E multiple remains unchanged at 25x (Dec'27).

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	PNGJL IN/Rs 598
Market cap	US\$ 779.1mn
Free float	17%
3M ADV	US\$ 1.6mn
52wk high/low	Rs 701/Rs 474
Promoter/FPI/DII	83%/1%/5%


Source: NSE | Price as of 10 Feb 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	75,860	93,542	117,912
EBITDA (Rs mn)	3,358	5,283	6,003
Adj. net profit (Rs mn)	2,183	3,585	3,985
Adj. EPS (Rs)	16.1	26.4	29.4
Consensus EPS (Rs)	16.1	23.8	29.1
Adj. ROAE (%)	20.9	20.7	18.9
Adj. P/E (x)	37.2	22.6	20.4
EV/EBITDA (x)	21.8	14.1	13.0
Adj. EPS growth (%)	22.3	64.2	11.2

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 01 February 2030**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "**Losses**") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "**MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.